Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...
Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024
Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024 Operating profit increased by ...
Novo Nordisk A/S (NYSE:NVO) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 6, 2024 Operator: Good day, and thank you for standing by. Welcome to the Third Quarter 2024 Novo Nordisk A/S Earnings Conference Call. At this time, all ...
Novo Nordisk reports 24% sales jump, driven by diabetes and obesity treatments
Novo Nordisk (NYSE:NVO) (CSE:NOVOb) reported strong growth for the first nine months of 2024, with sales jumping by 23% in Danish kroner and 24% at constant exchange rates, reaching DKK 204.7 billion.
How does Viking's weight loss med compare to ones from Novo, Eli Lilly?
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...
devdiscourse4d
Novo Nordisk's Obesity Drug Quest: High Stakes and New Challenges
Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% ...
pharmaphorum19h
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...